EDGE
Get a demo
Log In

Cellino Biotech

AI Drug Discovery
Segments:
AI Drug Discovery & Development
?
Product stage:
Seed
?

Cellino Biotech is a regenerative medicine company manufacturing stem cell-derived medicines by leveraging AI, machine learning, gene editing, and laser technologies to automate the manufacturing of cell therapies—allogeneic therapies (which use donor cells) and autologous therapies (which use the patient’s own cells). 

Cellino intended to solve the time-consuming manual work and high overhead costs required for stem cell-derived therapies by developing a system to manufacture induced pluripotent stem (iPS) cells. It uses a cell-editing laser system and machine learning to automate the process of eliminating sub-par cells that cannot be used for regenerative medicine (which is generally a labor-intensive process) and to process thousands of patient samples required for large-scale manufacturing of iPS cells. By 2025, it aims to build an autonomous human cell foundry.

The company has a long-term collaboration with the National Institutes of Health (NIH), which is initiating the first autologous iPS cells-derived clinical trial in the US. 

In its latest Series A funding round, the company raised USD 80 million to advance its AI platform and hardware capabilities. It also planned to build a Good Manufacturing Practices (GMP) standard facility for clinical trials.

AI Drug Discovery

AI Drug Discovery

Key stats
Featured companies
158
Total funding (USD)
25.1 Bn
Total addressable market (USD)
39.6 Bn
Key competitors
 
Loading...
Loading...
Loading...
Loading...
Product Overview
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Product Metrics
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Company profile
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...

EDGE Insights

Cell and gene therapy: Repairing the building blocks of life

Recent Updates

Funding
Jan 25, 2022
Cellino Biotech raises USD 80 million in Series A
AI Drug Discovery

Company Brief


HQ location:
750 Main St. Cambridge MA USA
Founded year:
2017
Employees:
11-50
Total Funding:
USD 97.5 million
Last Funding
USD 80.0 million, Jan 2022

Funding


Investors


No investor data is available

Funding data are powered by Crunchbase
arrow
menuarrow
Click here to learn more
Get a demo

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.